Abbott kicks off new research on software-guided, balloon-expandable TAVR system
Abbott has initiated a new clinical trial focused on the safety and effectiveness of its new transcatheter aortic valve replacement (TAVR) system, the Encantor Valve and Delivery System.
Unlike Abbott’s self-expanding Navitor TAVR system, which first secured U.S. Food and Drug Administration (FDA) approval in 2023 and CE mark approval in 2021, the Encantor valve is a balloon-expandable device. It was built to accommodate patients with a large aortic annulus and features open cells that provide coronary access. Once it is mounted on a deflated balloon and positioned inside the diseased aortic valve, clinicians use software-guided deployment to ensure the device is optimally expanded.
Researchers shared an early look at the new-look TAVR system at New York Valves 2026 in New York City, highlighting results from an early feasibility study. Overall, it was linked to “favorable” 30-day outcomes in terms of both safety and performance for the 11 patients who underwent treatment. Six-month data are now scheduled to be presented at the upcoming PCR London Valves 2026 conference.
This latest analysis, VOYAGER CE, will enroll up to 300 patients with symptomatic aortic stenosis in Europe and Australia as Abbott works toward securing CE mark approval.
“Our ambition is to give physicians the right technology for each patient,” Sandra Lesenfants, senior vice president of Abbott's structural heart business, said in a statement. “Our investigational Encantor system complements our Navitor self-expanding platform with a balloon-expandable option designed around physician insights, precise deployment and procedural ease of use. Advancing VOYAGER CE brings us another step closer to offering physicians a broader portfolio of structural heart solutions.”
The Encantor Valve and Delivery System is an investigational technology that has not received approval from the FDA or any other regulatory agencies.
